Dr. Lisa Ni explains how proton therapy offers more precision when treating brain and central nervous system tumors in ...
BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.
The Blood-Brain Barrier (BBB) is a highly selective interface that protects the brain by regulating the entry of nutrients, signaling molecules, and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
NEW ORLEANS, March 23, 2026 /PRNewswire/ -- 28bio today announced the company will present data demonstrating the ability to predict clinical seizure liability in small molecule drugs using human ...
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / ...
In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by ...
- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
The MarketWatch News Department was not involved in the creation of this content. Results show 83% sensitivity and 89% specificity in predicting whether small molecule drugs will cause clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results